There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Amicus Therapeutics Inc. (FOLD) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.29, or -2.79%, to $10.09. Volume reached 209,476 shares, with price reaching a high of $10.09 and a low of $10.09. Yahoo Finance discussed the stock recently as it posted Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $10.09 and fluctuated between $10.35 as its day high and $9.86 as its day low. The current market capitalization of Amicus Therapeutics Inc. is $2.91B. A total of 1.86 million shares were traded on the day, compared to an average of 3.08M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, FOLD has seen 3 BUY and 12 SELL insider trades, representing the acquisition of 16,410 and the disposition of 104,024 shares. Over the last 12 months, there were 35 BUYs and 61 SELLs from insiders. Insiders purchased 1,307,426 shares during that period but sold 828,193.
In the most recent transaction, Crowley John F sold 10,468 shares of FOLD for 10.66 per share on Sep 15. After the transaction, the Executive Chairman now owns 856,897 company shares. In a previous transaction on Sep 01, Campbell Bradley L sold 5,470 shares at 11.29 per share. FOLD shares that President & CEO owns now total 689,618.
Among the insiders who sold shares, Quimi Daphne disposed of 4,397 shares on Sep 01 at a per-share price of $11.29. This resulted in the Chief Financial Officer holding 335,312 shares of FOLD after the transaction. In another insider transaction, Crowley John F sold 11,346 shares at $11.30 per share on Sep 01. Company shares held by the Executive Chairman now total 867,365.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for FOLD in the last 3 months, the mean price target is $14.45 with high estimates of $20.00 and low estimates of $10.00. In terms of 52-week highs and lows, FOLD has a high of $12.96 and a low of $5.91.
As of this writing, FOLD has an earnings estimate of $-0.19 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $-0.16 per share and a lower estimate of $-0.21. The company reported an EPS of $-0.21 in the last quarter, which was 8.7% higher than expectations of $-0.23.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. FOLD’s latest balance sheet shows that the firm has $482.50M in Cash & Short Term Investments as of fiscal 2021. There were $440.13M in debt and $145.97M in liabilities at the time. Its Book Value Per Share was $0.59, while its Total Shareholder’s Equity was $307.37M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 13 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FOLD is Hold with a score of 4.50. A total of 8 analysts rated the stock as Buy while 0 rated it as Overweight while 5 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.